Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | WDR5 | P61964 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904916 | 0.82 | ALDH1A1 (0.51) | ALDH1A1HTTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL16501054 | 0.81 | LMNA (0.51) | ALDH1A1HTTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL8114936 | 0.79 | CYP19A1 (0.45) | ALDH1A1LMNAKMT2AMAPTRAB9A | |
| SCHEMBL7866969 | 0.79 | ALDH1A1 (0.58) | ALDH1A1HTTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL30736225 | 0.77 | ALDH1A1 (0.52) | ALDH1A1HTTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL21808580 | 0.77 | ALDH1A1 (0.52) | ALDH1A1HTTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL30879319 | 0.77 | CYP19A1 (0.54) | ALDH1A1SMN1; SMN2WDR5LMNAHTR6 | |
| SCHEMBL2910168 | 0.76 | HTT (0.47) | ALDH1A1HTTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL30879346 | 0.76 | CYP19A1 (0.45) | ALDH1A1HTTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL30879417 | 0.75 | CYP19A1 (0.44) | ALDH1A1HTTSMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334301-B1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK SERONO SA (CH) | 2018-02-14 | — | — | EP | disclosed |
| US-8815872-B2 | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815872-B2 | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815872-B2 | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-2334301-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | Merck Serono SA (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010028116-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028116-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | AURKC, AURKA, AURKB | ALDH1A1 4424/4885HTT 4089/4885SMN1; SMN2 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.